Trial Profile
A Multicenter, Open-Label, Phase 2 Trial to Evaluate the Safety and Activity of Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2020
Price :
$35
*
At a glance
- Drugs Efgartigimod alfa (Primary) ; Efgartigimod alfa (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors argenx
- 14 Jul 2020 Status changed from planning to discontinued.
- 02 Nov 2018 New trial record
- 25 Oct 2018 According to an Argenx media release, the company plans to initiate this trial in the first half of 2019.